Clinical Trials in Marlton, New Jersey
25 recruiting
Showing 1–20 of 25 trials
Recruiting
Not Applicable
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
HypertensionHypertension, SystolicHypertension,Essential
Orchestra BioMed, Inc500 enrolled98 locationsNCT06059638
Recruiting
Not Applicable
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Metabolic SyndromeDiabetes Mellitus, Type 2Prediabetes
Cleerly, Inc.7,500 enrolled115 locationsNCT06112418
Recruiting
Phase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Major Depressive Disorder (MDD)
Draig Therapeutics Ltd300 enrolled24 locationsNCT07300969
Recruiting
Phase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.153 enrolled12 locationsNCT07284667
Recruiting
Phase 4
A Study to Evaluate the Effect of KarXT on Urological Safety
Schizophrenia
Bristol-Myers Squibb60 enrolled14 locationsNCT07221877
Recruiting
Phase 1
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
HealthyAlzheimer Disease
Eli Lilly and Company128 enrolled9 locationsNCT06657768
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034
Recruiting
Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Hoffmann-La Roche1,290 enrolled462 locationsNCT05595642
Recruiting
Not Applicable
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Persistent Atrial Fibrillation
Boston Scientific Corporation407 enrolled32 locationsNCT06735534
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled564 locationsNCT07037459
Recruiting
Phase 3
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
Generalized Anxiety Disorder
Definium Therapeutics US, Inc.200 enrolled36 locationsNCT06741228
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled60 locationsNCT06894212
Recruiting
Phase 3
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Weight Loss
Viking Therapeutics, Inc.1,100 enrolled134 locationsNCT07104383
Recruiting
Phase 2
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
Schizophrenia
AbbVie268 enrolled7 locationsNCT07145918
Recruiting
Phase 2
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
Bipolar Disorder Depression
Autobahn Therapeutics, Inc.35 enrolled15 locationsNCT06869187
Recruiting
Global Paradise System US Post Approval Study
Cardiovascular DiseasesHypertensionVascular Diseases
ReCor Medical, Inc.1,000 enrolled34 locationsNCT06297291
Recruiting
Phase 3
Randomized Withdrawal Study in Patients With Schizophrenia
Schizophrenia
Vanda Pharmaceuticals400 enrolled22 locationsNCT06961968
Recruiting
Phase 1
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
Schizophrenia
Bristol-Myers Squibb48 enrolled8 locationsNCT07061288
Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Heart FailureArrhythmiaBradycardia+1 more
Medtronic20,000 enrolled318 locationsNCT00271180